Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Running, not enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Glaucoma, Ocular Hypertension

In brief

The study purpose is to evaluate the safety of T4090.

Key facts

Study ID

NCT05389267

Run by

Laboratoires Thea

People needed

120

Starts

2022-07-05

Expected to finish

2024-12-31

Last updated by the study team

2024-02-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent dated and signed.
• Both eyes diagnosed open-angle glaucoma or ocular hypertension

You may not qualify if…

• History of trauma, infection, clinically significant inflammation within the previous 6 months
• Known or suspected hypersensitivity to one of the components of the Investigational Medicinal Product(s)
• Pregnancy or breast-feeding

Where it is running

• Dr EL-HARAZI — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.